Taiho Oncology’s cancer drug Lytgobi is the third FDA-approved cancer drug for bile duct cancer driven by FGFR2 genetic alterations. The accelerated approval for Taiho’s drugs follows regulatory nods for products from Incyte and QED Therapeutics that address the same genetic signature.
